Article: Favorable Soriatane Cost-Effectiveness Analysis is Published in Leading Managed Care Journal.

PALO ALTO, Calif. -- Connetics Corporation (Nasdaq:CNCT), a specialty pharmaceutical company that develops and commercializes dermatology products, announced today that a study comparing the cost-effectiveness of systemic treatments for psoriasis was published in the May issue of Drug Benefit Trends after being presented in a poster at the 17th Academy of Managed Care Pharmacy annual meeting held April 20th to 23rd in Denver. The publication demonstrates that Soriatane(R) (acitretin) is more cost-effective than biologics. Additionally, in combination with UV light therapy, Soriatane demonstrated a highly favorable cost-to-benefit profile in comparison to the other ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!